The
complement system consists of more than 30
proteins and has 3 types of activation pathways: classical,
lectin and alternative pathways. The
complement system not only has a role in innate immunity but also works as an antibody-dependent effecter to eliminate pathogens. It is useful to measure serum levels of CH50, C3 and C4 in patients with immune-mediated diseases. While increased levels of CH50 are associated with non-specific
inflammation, decreased levels of CH50 in combination with normal or decreased levels of C3 and C4 are associated with specific immune-mediated diseases. Recent studies have demonstrated that the defect in the clearance of
immune complexes and apoptotic cells is associated with
autoimmune disease. Mice deficient in Clq show a lupus-like phenotype with the appearance of
antinuclear antibodies and
glomerulonephritis due to a defect in the clearance of
immune complexes and apoptotic cells. This at least explains the paradox that, in humans, deficiency in an early
complement component is a major risk factor for SLE. It is demonstrated that mutations in
factor H,
membrane cofactor protein (MCP) and
factor I gene are associated with
atypical hemolytic uremic syndrome. Since the
complement system is a central mediator of
inflammation, it is recognized as a promising therapeutic target. Anti-C5
monoclonal antibody was developed to block the final stage of complement activation.
Pexelizumab is a single chain, short-acting anti-C5 antibody and is used for reperfusion after
myocardial infarction, or for
coronary artery bypass graft surgery with
cardiopulmonary bypass.
Eculizumab is a long-acting anti-C5 antibody used for
paroxysmal nocturnal hemoglobinuria,
rheumatoid arthritis,
membranous glomerulonephritis with promising results.